NYSE:BSXMedical Equipment
Boston Scientific Tests Combined Cardiac Devices In OPTION EMEA Trial
Boston Scientific (NYSE:BSX) has started the OPTION-EMEA clinical trial in real world hospital settings across Europe.
The study evaluates the combined use of two cardiac devices for patients with atrial fibrillation and stroke prevention.
The trial is designed to assess safety and potential benefits of this combined therapy approach in routine clinical practice.
For investors watching NYSE:BSX, this new trial comes as the shares trade at $76.29. The stock is up 65.0% over the past 3 years...